gefitinib has been researched along with 10-propargyl-10-deazaaminopterin in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (10-propargyl-10-deazaaminopterin) | Trials (10-propargyl-10-deazaaminopterin) | Recent Studies (post-2010) (10-propargyl-10-deazaaminopterin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 119 | 21 | 85 |
| Protein | Taxonomy | gefitinib (IC50) | 10-propargyl-10-deazaaminopterin (IC50) |
|---|---|---|---|
| Folate receptor alpha | Homo sapiens (human) | 0.168 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0007 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.057 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
2 review(s) available for gefitinib and 10-propargyl-10-deazaaminopterin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |